ALX Oncology Holdings Inc.
ALXO
$2.11
-$0.07-3.21%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 5.45M | 7.93M | 7.08M | 6.10M | 6.87M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 23.47M | 31.82M | 30.61M | 32.57M | 41.53M |
Operating Income | -23.47M | -31.82M | -30.61M | -32.57M | -41.53M |
Income Before Tax | -25.95M | -30.75M | -29.16M | -30.71M | -39.40M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -25.95M | -30.75M | -29.16M | -30.71M | -39.40M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -25.95M | -30.75M | -29.16M | -30.71M | -39.40M |
EBIT | -23.47M | -31.82M | -30.61M | -32.57M | -41.53M |
EBITDA | -23.28M | -31.61M | -30.40M | -32.34M | -41.31M |
EPS Basic | -0.49 | -0.58 | -0.55 | -0.58 | -0.76 |
Normalized Basic EPS | -0.27 | -0.36 | -0.35 | -0.36 | -0.48 |
EPS Diluted | -0.49 | -0.58 | -0.55 | -0.58 | -0.76 |
Normalized Diluted EPS | -0.27 | -0.36 | -0.35 | -0.36 | -0.48 |
Average Basic Shares Outstanding | 53.45M | 53.36M | 52.80M | 52.69M | 51.83M |
Average Diluted Shares Outstanding | 53.45M | 53.36M | 52.80M | 52.69M | 51.83M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |